dasolampanel dasolampanel dasolampanel (inn, usan, code name ngx-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the ampa and kainate receptors which was under development by raptor pharmaceuticals/torrey pines therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. it was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed. dasolampanelclinical dataatc codenoneidentifiers iupac name (3s,4as,6s,8ar)-6-(3-chloro-2-(1h-tetrazol-5-yl)phenoxy)decahydroisoquinoline-3-carboxylic acid cas number503294-13-1pubchem cid51049972chemspider25948207unii1p85d6be9kkeggd10107chemical and physical dataformulac17h20cln5o3molar mass377.83 g·mol−13d model (jsmol)interactive image smiles c1cc(c(c(c1)cl)c2nnn2)o3cc4cn(c4c3)c(=o)o inchi inchi=1s/c17h20cln5o3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19h,4-8h2,(h,24,25)(h,20,21,22,23)/t9-,10+,11-,13-/m0/s1key:lakqpsqcicnzii-nohgzbonsa-n